Amgen's Blincyto meets in ALL

Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) met the primary endpoint in the Phase II BLAST trial to treat minimal residual disease (MRD)-positive precursor B cell acute lymphoblastic leukemia (ALL).

Among 113 patients in the study, 88 (78%) achieved a complete MRD response after a six-week cycle of treatment with daily 15 ug/m2 IV for the first 28 days. There were two treatment-related adverse events of subdural hemorrhage and pneumonitis in conjunction with influenza. Data were presented at the American Society of Hematology (ASH) meeting in San Francisco. ...